07.24.17
Laurent Fischer, M.D. has been appointed director of CTI BioPharma. Dr. Fischer has more than 20 years of experience in developing and commercializing biopharmaceutical medicines and currently serves as liver therapeutic area head at Allergan, following its acquisition of Tobira Therapeutics in 2016, where he previously served as chief executive officer.
"Laurent has significant experience developing and commercializing novel medicines and a track record of creating value for shareholders. We are pleased to have him join the Board and look forward to working with him," said Adam R. Craig, M.D., Ph.D., president and chief executive officer of CTI BioPharma.
Dr. Fischer has also served as senior advisor on the Frazier Healthcare Partners' Life Sciences team since March 2017. He was previously chairman and chief executive officer of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy for Liver Cancer acquired for $150 million by Sillajen. He was co-founder, president and chief executive officer of Ocera Therapeutics and held senior positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology.
"Laurent has significant experience developing and commercializing novel medicines and a track record of creating value for shareholders. We are pleased to have him join the Board and look forward to working with him," said Adam R. Craig, M.D., Ph.D., president and chief executive officer of CTI BioPharma.
Dr. Fischer has also served as senior advisor on the Frazier Healthcare Partners' Life Sciences team since March 2017. He was previously chairman and chief executive officer of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy for Liver Cancer acquired for $150 million by Sillajen. He was co-founder, president and chief executive officer of Ocera Therapeutics and held senior positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology.
